From c698209637c815849fd24bf3c7c5bf3fb736d68a Mon Sep 17 00:00:00 2001 From: Kelsey Hales Date: Sat, 2 Aug 2025 20:36:24 +0000 Subject: [PATCH] =?UTF-8?q?Add=20'FDA=20Pauses=20PepGen=E2=80=99s=20DMD=20?= =?UTF-8?q?Drug=20Trial=20in=20the=20US'?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md | 1 + 1 file changed, 1 insertion(+) create mode 100644 FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md diff --git a/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md b/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md new file mode 100644 index 0000000..12d8d8e --- /dev/null +++ b/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md @@ -0,0 +1 @@ +
The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, Check this out placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision \ No newline at end of file